SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Åleskog Anna)
 

Sökning: WFRF:(Åleskog Anna) > In vitro evaluation...

In vitro evaluation of clinical activity and toxicity of anticancer drugs using tumor cells from patients and cells representing normal tissues

Haglund, Caroline (författare)
Uppsala universitet,Klinisk farmakologi
Åleskog, Anna (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper,Division of Haematology
Nygren, Peter (författare)
Uppsala universitet,Klinisk farmakologi,Enheten för onkologi,Nygren
visa fler...
Gullbo, Joachim (författare)
Uppsala universitet,Klinisk farmakologi
Höglund, Martin (författare)
Uppsala universitet,Hematologi,Division of Haematology
Wickström, Malin (författare)
Uppsala universitet,Klinisk farmakologi
Larsson, Rolf (författare)
Uppsala universitet,Klinisk farmakologi
Lindhagen, Elin (författare)
Uppsala universitet,Klinisk farmakologi
visa färre...
 (creator_code:org_t)
2011-10-09
2012
Engelska.
Ingår i: Cancer Chemotherapy and Pharmacology. - : Springer Science and Business Media LLC. - 0344-5704 .- 1432-0843. ; 69:3, s. 697-707
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • PURPOSE: The aim of this study was to evaluate a phenotypic cell panel with tumor cells from various patients and normal cells for preclinical profiles of antitumor efficacy and toxicity of anticancer drugs.METHODS: The antitumor activity of fourteen anticancer drugs was tested in over one hundred tumor samples from patients with solid or hematological malignancies. Drug activity against four normal cell types was used for the assessment of normal tissue toxicity. In vitro activity of the drugs was compared with indications approved by the Food and Drug Administration and established adverse event profiles.RESULTS: In general, in vitro drug activity in tumor cells from patients reflected known clinical activity of the drugs investigated. For example, the clinical activity of imatinib in chronic myeloid leukemia was clearly detected in the tumor panel. Further, and in accordance with clinical use, cisplatin and bortezomib showed high activity in ovarian cancer and myeloma samples, respectively. The normal cell models roughly reflected known clinical toxicity profiles and were able to detect differences in therapeutic index, e.g., between targeted drugs and classical cytotoxic agents. For example, the high tolerability of imatinib and the well-known renal toxicity of cisplatin were demonstrated.CONCLUSIONS: In preclinical drug development, primary tumor cells from patients can be used for the prediction of cancer diagnosis-specific activity and may aid in the selection of diagnoses for clinical trials. By using tumor and toxicity panels together, information about therapeutic index may be derived, which may be useful when choosing among drug candidates with similar tumor effects.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy